Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

13 Comorbid Conditions Decrease Survival, Increase Mortality in Elderly Breast Cancer Patients

TOP - August 2011 Vol 4, No 5 published on August 25, 2011 in Breast Cancer

For breast cancer patients aged 66 years and older, nurses should consider comorbidities when discussing prognosis, according to an analysis of Surveillance, Epidemiology and End Results–Medicare data.

In a US population of 64,034 patients diagnosed with breast cancer at a median age of 75 years, Patnaik and colleagues identified 13 comorbid conditions associated with decreased overall survival and increased all-cause mortality (Table). Among the study population, 58% had none of the selected comorbidities, 28.0% had 1 comorbidity, 8.8% had 2 comorbidities, and 4.9% had ≥3 of the conditions.

Table 1
Comorbid Conditions Associated with Decreased Survival

Kaplan-Meier survival curves showed that comorbidities are associated with survival, meaning that for a patient with comorbid conditions diagnosed at an early stage, that patient had similar or worse survival than a patient with no comorbid conditions diagnosed at a later stage.

The investigators concluded that their findings suggest that “careful attention to the effective management of comorbid conditions, as well as to the management of a patient’s cancer, may result in longer overall survival for older breast cancer patients.”

Related Items
Olaparib Extends Disease-Free Survival in Patients with Early-Stage Breast Cancer and BRCA Mutation
William King
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Breast Cancer
Tucatinib plus Trastuzumab and Capecitabine Triplet Maintains Survival Benefit in HER2-Positive Metastatic Breast Cancer: Updated Results from HER2CLIMB Trial
Charlie Dawson
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Breast Cancer
Cryoablation Appears Safe and Effective in Low-Risk, Early-Stage Breast Cancer
William Ackerman
TOP - July 2021 Vol 14, No 4 published on July 20, 2021 in Breast Cancer
Pembrolizumab plus Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
Patricia Stewart
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Breast Cancer
Abemaciclib plus Endocrine Therapy Offers Invasive Disease–Free Survival Benefit in Patients with High-Risk, HR-Positive, Early-Stage Breast Cancer
Patricia Stewart
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Breast Cancer
Breast Cancer Year in Review Introduction
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Preliminary Results from a Phase 2 Trial of Fulvestrant/Palbociclib as First-Line Therapy in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Endocrine-Sensitive Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Last modified: July 22, 2021